目的了解南京地区24家医院降糖药的临床使用情况和变化趋势。方法比较2002～2003年药品购入数据,采用MicrosoftExcel进行统计和分析。结果磺酰脲类和双胍类药仍然是临床主要使用的降糖药,占所有降糖药使用DDDs总值的70%左右,糖苷酶抑制剂和胰岛素在临床也有较广泛的使用,占所有降糖药使用DDDs总值的20%以上,其他新型降糖药和中成药的使用只占DDDs总值的10%以下。二甲双胍、格列齐特、阿卡波糖、格列吡嗪、胰岛素为临床一线用药。结论南京地区降糖药的使用结构比较合理。费用是糖尿病患者能否规范、连续用药的一个重要的影响因素。 Objective To understand the clinical use and trend of hypoglycemic agents in 24 hospitals in Nanjing. Methods The drug purchase data from 2002 to 2003 were compared and statistically analyzed with Microsoft Excel. Results Sulfonylureas and biguanides are still the main clinical hypoglycemic agents, accounting for about 70% of the total DDDs used by all hypoglycemic agents. Glycopeptide inhibitors and insulin are also widely used in clinical practice, The total use of DDDs for sugar drugs is over 20%. The use of other new hypoglycemic agents and proprietary Chinese medicines only accounts for less than 10% of the total DDDs. Metformin, gliclazide, acarbose, glipizide, insulin for the clinical front line. Conclusion The use of hypoglycemic agents in Nanjing is reasonable. Expense is the standard of diabetic patients, continuous medication is an important factor.